The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy
Abstract
To assess whether extended treatment with interferon improves the outcome of hepatitis B e antigen (HBeAg)–negative chronic hepatitis B, 101 consecutive patients were treated with 6 MU of interferon alfa 2b 3 times weekly for 24 months. During the 68–month study, 30 patients (30%) had a sustained response (i.e., normal serum transaminase levels and undetectable hepatitis B virus DNA by non–polymerase chain reaction [PCR] assays), and 15 cleared serum surface antigen. Twenty–five nonresponders, 16 relapsers, and 30 who discontinued treatment were considered treatment failures. Multivariate analysis predicted a sustained response for young age (odds ratio, 0.94; 95% confidence interval, 0.89–0.99; P = .041) and high pretreatment serum levels of immunoglobulin M (IgM) anti–hepatitis B core antigen (HBc) (odds ratio, 4.52; 95% confidence interval, 1.63–12.5; P = .004). Liver disease progressed in none of the sustained responders but in 16 with treatment failure (0% vs. 22%, P = .002); hepatocellular carcinoma (HCC) developed with similar frequency in both groups (7%). Overall, estimated 8–year complication–free survival was longer for the 30 sustained responders than the 71 patients with treatment failure (90% vs. 60%, P < .001), but 8–year patient survival was similar in the 2 groups (100% and 90%). Short complication–free survival was predicted by failure to respond to interferon (hazard ratio, 7.8; 95% confidence interval, 1.8–34.0; P = .006) and high scores for liver fibrosis (hazard ratio, 1.71; 95% confidence interval, 1.17–2.50; P = .005). In conclusion, 24 months of treatment with interferon alfa 2b led to sustained disease suppression in a significant proportion of patients with HBeAg–negative chronic hepatitis B. (Hepatology 2003;37:756–763.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Partial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, Y.-F., Kao, J.-H., Piratvisuth, T., Chan, H. L. Y., Chien, R.-N., Liu, C.-J., Gane, E., Locarnini, S., Lim, S.-G., Han, K.-H., et al. (2012) · Hepatology International · doi:10.1007/s12072-012-9365-4 · Cited by 1,038
Metadata
- Authors
- Lampertico, P., Del Ninno, E., Viganò, M., Romeo, R., Donato, M. F., Sablon, E., Morabito, A., & Colombo, M.
- Venue
- Hepatology
- Published
- 2003-04
- Volume
- 37
- Issue
- 4
- Pages
- 756-763
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2097754581
- Cited by
- 215
- References
- 1
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy. https://app.cochat.ai/papers/10.1053/jhep.2003.50148
- The paper
- Lampertico, P., Del Ninno, E., Viganò, M., Romeo, R., Donato, M. F., Sablon, E., Morabito, A., & Colombo, M. (2003). Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy. Hepatology. https://doi.org/10.1053/jhep.2003.50148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.